Drug Profile
Research programme: bispecific antibody therapeutics - Merus/ KBI Biopharma
Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Merus; Selexis
- Developer KBI Biopharma; Merus
- Class Bispecific antibodies
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer